Hepatitis news and hepatitis widget

Hepatitis C virus (HCV) is one of the more common causes of chronic liver disease in world with a variety of extrahepatic complications such as essential mixed cryoglobulinemia, membranoproliferative glomerulonep hritis, autoimmune thyroiditis, sialadenitis, and cardiomyopathy. IPF is present in patients with chronic HCV infection. However, there is little or no information on the yearly cumulative incidence and risk factors on the development rate of IPF in patients with HCV.

Liver fibrosis occurs in the setting of chronic injury caused by different etiologies constituting a serious worldwide public health problem. In addition to schistosomiasis, hepatopathies due to alcohol, viral hepatitis, drugs, metabolic and autoimmune diseases, and congenital abnormalities are important causes of liver fibrosis. New therapeutic strategies aiming to minimize damages caused by hepatic fibrogenesis in chronic liver diseases are of great interest.

HEPATOLOGY: A new regulator in the liver: miR15a controls the development of cysts Polycystic liver and kidney diseases are a family of disorders that are characterized by a range of symptoms. For example, individuals with ADPKD have multiple cysts in both their liver and their kidneys, whereas individuals with ARPKD usually only have cysts in their kidneys (although cysts can develop in the liver later in life) and individuals with ADPLD only have cysts in their liver.

Management of hepatitis B is a challenge for physicians and patients due to an incomplete understanding of the disease course, complex treatment indications, and the lack of large studies focusing on important health outcomes. To examine these issues, the NIH convened an independent, impartial panel this week to weigh the available evidence on the management of hepatitis B. While more than 95 percent of U.S.